Main Article Content
The current study focuses on increasing antibacterial action of clarithromycin and its formulation. Although various clarithromycin tablets are available in the market, but its bioavailability is around 45% and dose given is 250-500mg twice daily. We propose to make use of Piperine for the first time in the prepared formulations to enhance its bio-efficacy and reduce dose. The literature has described Piperine as a potent bio-efficacy booster. Preformulation studies of pure drug Clarithromycin was done by determining its melting point, FTIR, DSC and λmax determination, Standard Calibration curve, etc. which confirmed drug. The compatibility of the drug with the excipients was then assessed using DCS, XRD, and SEM, which revealed that the drug is compatible with every excipient. Zones of inhibition against Staphylococcus aureus and Escherichia coli were measured after mixing CL and piperine in various ratios (1:0.5, 1:1, 1:1.5, 1:2, 1:3, and 1:4). Initially MIC of standard drug was evaluated against Staphylococcus aureus and Escherichia coli. Out of all the ratios, the 1:2 ratio displayed the greatest activity, following which a persistent zone of inhibition was seen. The optimized ratio, 1:2, was employed to develop the formulation. Gastro retentive effervescent floating tablets of Clarithromycin using different concentrations of HPMC K15, Polyethylene Oxide and Sodium Bicarbonate were taken. Formulation was optimized by using Design Expert 11 software, total 9 batches F1- F9 were formulated using two independent variables PEO (X1) and HPMC K15 (X2) whereas Floating Lag Time (Y1) and % Drug Release after 24 hr (Y2) were selected as dependent variable. Out of all these formulations F7 was found to be the optimized formulation. All the formulations were evaluated by various parameters and the results obtained were within the limits. Optimized formulation was also studied for release kinetics.
G. Bachir raho and B. Abouni “Escherichia coli and Staphylococcus aureus most common source of infection”, FORMATEX; 2015, 637-648.
M. Balouiri, M. Sadiki, et. al. “Methods for in vitro evaluating antimicrobial activity: A review” Journal of Pharmaceutical Analysis; 2016, 6, 71–79.
C. Valgas, S. de Souza, et. al. “Screening methods to determine antibacterial activity of natural products”, Brazilian Journal of Microbiology; 2007, 38, 369-380.
T. Suryaprakash, S. Prabu, et. al. “Formulation and evaluation of oral controlled release matrix tablet using hydrophilic polymer”, International Journal of Pharmaceutical Science and Nanotechnology; 2013, 6 (4), 2255-2259.
N. Khan, F Hassan et. al. “Antimicrobial activity of erythromycin and clarithromycin against clinical isolates of Escherichia coli, Staphylococcus aureus, Klebsiella and Proteus by disc diffusion method”, Pak J Pharm Sci.; 2011, 24(1), 25-9.
E. Hume, M Moreau et. al. “Clarithromycin for experimental Staphylococcus aureus keratitis”, Current Eye Resource; 1999,18(5), 358-62.
Carlos, V Gutierres, et. al. “Piperine, a Natural Bioenhancer, Nullifies the Antidiabetic and Antioxidant Activities of Curcumin in Streptozotocin-Diabetic Rats”, PLOS ONE; 2014, 1-21.
S. Acharya, H. Momin, et. al. “Review of Piperine as a Bio-enhancer”, American Journal of PharmTech Research; 2012, 2(2), 2249-3387.
S. Sharma, M. Kumar, et. al.“Piperine as an inhibitor of Rv1258c, a putative multidrug efflux pump of Mycobacterium Tuberculosis”, J Antimicrob Chemother; 2010, 65, 1694–1701.
Lan Zou, Yue-Ying Hu, et. al. “Antibacterial mechanism and activities of black pepper chloroform extract”, J Food Sci Technol; 2015, 52(12), 8196–8203.
S. Rani, N Saxena, et. al. “Antimicrobial Activity of Black Pepper (Piper nigrum L)”, Global Journal of Pharmacology; 2013, 7 (1), 87-90.
K. Barve, K. Ruperal “Effect of Bioenhancers on Amoxicillin bioavailability”, ADMET & DMPK; 2015, 3(1), 45-50.
S. Khatri, F. Ahmed, et. al. “Formulation and evaluation of floating gastroretentive capsules of Acyclovir with piperine as a bioenhancer”, The Pharma Innovation Journal; 2015, 3(11), 78-81.
S Mansuri, A. Pathak, et. al. “Development and validation of chemometric assisted uv spectrophotometric and rplc-pda methods for the simultaneous in vitro analysis of Isoniazid, Rifampicin and Piperine in their pharmaceutical formulation”, Indo American Journal of Pharmaceutical Research; 2014, 4(1), 540- 553.
P. Pingale, P. Ravindra, et. al. “Effect of piper nigrum on in-vitro release of Rifampicin microspheres”, Asian J Pharm Clin Res; 2013, 6(5), 79-83.
Ferrero, J. L., Bopp, et al., “Metabolism and disposition of clarithromycin in man”, Drug Metab. Dispos; 2000, 18: 441-44.
J. Kunchithapatham, R. Manavalan, et. al “Studies on effect of piperine on oral bioavailability of ampicillin and norfloxacin”, Afr. J. Trad. CA; (2008, 5 (3), 257 – 262.
A. Nayak, R Maji, et. al. “Gastroretentive drug delivery systems: a review”, Asian Journal of Pharmaceutical and Clinical Research; 3(1), 2010, 2-10.
Bhowmik D, Chiranjib B, et. al., “Floating drug delivery system: a review”, Der Pharmacia Lettre; 2009, 1(2): 199–218.
Chien YW, et. al., “Oral drug delivery and delivery system in novel drug delivery Systems, ed, 50, Marcel Dekker publication, New York, 1992.
Chien YW, et. al., “Rate‐control drug delivery systems: controlled release vs. sustained release”, Med Prog Techn; 1989, 15: 21‐46.
Lachman L, Liberman HA. The Theory and Practice of Industrial Pharmacy, 7th Edn. 2009, 297, 300
W.H.O., “Global Health Observatory (GHO) Data,” Geneva, Switzerland, 2016; 6-10.
Indian Pharmacopoeia, Published by the Indian Pharmacopoeia Commission, Ghaziabad, 2007; 2, 701-3.
Indian Pharmacopoeia, Published by the Indian Pharmacopoeia Commission, Ghaziabad; 2007, 2, 576-78.
WHO: World Health Organisation (Geneva, Switzerland) www.who.int
NCCLS: National Committee for Clinical Laboratory Standards www.nccls.org.
NEQAS: National External Quality Assessment Scheme www.ukneqas.org.uk
NCTC: National Collection of Type Cultures www.ukncc.co.uk
JAC: The Journal of Antimicrobial Chemotherapy. Supplement S1 to Volume 48 July, 2001 Antimicrobial Susceptibility Testing. A report of the Working Party on Susceptibility Testing of the British Society for Antimicrobial Chemotherapy. Available from: www.jac.oupjournals.org/content/vol48/suppl_1/
Pumerantz A, Muppidi K, et. al., “Preparation of liposomal vancomycin and intracellular killing of meticillin-resistant Staphylococcus aureus (MRSA)”, Int. J. Antimicrob. Agents; 2011, 37:140 –144.
Kadota J, Mukae H, et. al., “Long-term efficacy and safety of clarithromycin treatment in patients with diffuse panbronchiolitis”, Respir. Med.; 2003, 97:844–850.
Kiran N, Azam S, et. al., “Clarithromycin induced digoxin toxicity: case report and review”, J. Pak. Med. Assoc.; 2004, 54:440–441.
Clinical and Laboratory Standards Institute, Performance standards for antimicrobial susceptibility testing; sixteenth informational supplement, CLSI document M100-S16CLSI, Wayne, PA (2006).
European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID).
Determination of minimum inhibitory concentrations (MICs) of antibacterial agents by broth dilution. Clin. Microbiol. Infect; 2003, 9, 9-15.
Kahlmeter, G. et al. European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria. J. Antimicrob. Chemother; 2003, 52, 145–148.
Al-Tawfiq JA, Antony A, et. al., “Antimicrobial resistance of Klebsiella pneumoniae in a Saudi Arabian hospital: results of a 6-year surveillance study, 1998- 2003. J. Infect. Chemother.;2007, 13(4): 230-234
Drago L, Ripa S, “Activity of ceftibuten, cefaclor, azithromycin, clarithromycin, erythromycin and telithromycin against streptococcus pyogenes clinical isolates with different genotypes and phenotypes. Chemotherapy; 2005, 51(5): 268-271.
Groppo FC, Castro FM, “Antimcrobial resistance of Staphylococcus aureus and oral streptococci strains from high risk endocarditis patients”, Gen. Dent, 2005, 53(6): 410-413
Nanavaty, J., Mortensen, J.E. & Shryock, T.R. The effects of environmental conditions on the in vitro activity of selected antimicrobial agents against Escherichia coli. Curr. Microbiol; 1998, 36, 212–215.
D’amato, R.F., Thornsberry, C., et. al., “Effect of calcium and magnesium ions on the susceptibility of Pseudomonas species to tetracycline, gentamicin polymyxin B, and carbenicillin”, Antimicrob. Agents Chemother; 1975, 7, 596–600.
Rhomberg, P.R., Sader, et. al., “Reproducibility of daptomycin MIC results using dry-form commercial trays with appropriate supplemental calcium content”, Int. J. Antimicrob. Agents; 2005, 25, 274–276.
Bowdish, D.M., Davidson, et. al., “Effect of NaCl and nafcillin on penicillin-binding protein 2a and heterogeneous expression of methicillin resistance in Staphylococcus aureus”, Antimicrob. Agents Chemother; 1987, 31, 1982–1988.
Pankey, G.A. & Sabath, et. al., “Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections”, Clin. Infect. Dis.; 2004, 38, 864–870.
Biedenbach, D.J., et. al., “Validation of Etest for seven antimicrobial agents using regulatory criteria for the assessment of antimicrobial susceptibility devices”, Diagn. Microbiol. Infect. Dis.; 1997, 27, 1–5.
Andrews, J.M. & Wise, R. “Comparison of the Etest with a conventional agar dilution method in evaluating the in vitro activity of moxifloxacin”, J. Antimicrob. Chemother; 2000, 45, 257–258.
Steward, C.D, et al., “Antimicrobial susceptibility testing of carbapenems: multicenter validity testing and accuracy levels of five antimicrobial test methods for detecting resistance in Enterobacteriaceae and Pseudomonas aeruginosa isolates”, J. Clin. Microbiol.; 2003, 41, 351–358.
Calvet, X., Garcia, N., et. al., “A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin, and either metronidazole or amoxicillin for treating Helicobactor pylori infection”, Aliment. Pharmacol. Ther.; 2000, 4: 603-609.
Dore, M.P., Leandro, G., et. al., “Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobactor pylori therapy”, Dig. Dis. Sc;2000, 45: 68-76.
Endo, H., Yoshida, H., et. al., “Localization of 14C amoxicillin in rat gastric tissue when administered with lansoprazole and clarithromycin”, J. Antimicrob. Chemother; 2001, 48: 923–926.
Erah, P., Goddard, A., et. al., “The stability of amoxicillin,clarithromycin and metronidazole in gastric juice: Relevance to the treatment of Helicobactor pylori infection”, J. Antimicrob. Chemother; 1997, 39: 5-12.
Fraschini, F., Scaglione, F.,et. al.,” Clarithromycin, clinical pharmacokinetics”, Clin. Pharmacokinet; 1993, 25:189-204.
Amini, H., Ahmadiani, A., et. al., “Sensitive determination of clarithromycin in human plasma by high performance liquid chromatography with spectrophotometric detection”. J.Chromatogr. ;2005, 817: 193–197.
Chu, S.Y., Sennello, et. al., “Simultaneous determination of clarithromycin and 14-hydroxy-clarithromycin in plasma and urine using HPLC with electronical detection”, J. Chromatogr. Biomed. App; 1991, 571: 199 – 208.
M. Lagnajit, V. Gali, et. al. “Formulation and In vitro Evaluation of Gastroretentive Floating Tablets of Macrolide Antibiotic Based on Effervescent Technology Using Clarithromycin as a model drug “, UK Journal of Pharmaceutical and Biosciences; 2014, 2(6), 01-08.
D. Ptingrao, P. Kadu, et. al. “Formulation and evaluation of clarithromycin gastroretentive dosage form”, J. Chem. Pharm. Res.; 2014, 6(7), 82-89.
S, Santha, T Rao, et. al. “Formulation and evaluation of Clarithromycin gastroretentive dosage form”, Int J Pharmacy and Pharm Sci; 2010, 2(3), 48 – 55.
A. Margret, D. Bhowmik, et. al. “Formulation and evaluation of mucoadhesive oral tablet of Clarithromycin”, T. Pharm. Res.; 2009, 2; 30-42.
N. Muralidhar, C. Gonugunta, et. al. “Formulation and Evaluation of Gastroretentive Dosage Forms of Clarithromycin”, AAPS Pharm Sci Tech; 2008, 9(1), 232- 237.
Ashok KD, Guru PM, et. al., “Formulation and In vitro evaluation of famotidine floating tablets by lipid solid dispersion spray drying technique”, International Journal of Research in Pharmacy and Chemistry; 2012, 2(4): 996–1000
Baek N, Park K, et. al., “Control of the swelling rate of superporous hydrogels”, J. Bioactive Compatible Polymers; 2001, 16: 47–57.
Gande S, Rao YM, et. al., “Sustained–Release Effervescent Floating Matrix Tablets of Baclofen: development, optimization and In vitro–in vivo evaluation in healthy human volunteers”, DARU; 2011, 19: 2011.
Hilton, A. K, P. Deasy, et. al.,“In vitro and in vivo evaluation of an oral sustained release floating dosage form of Amoxycyllin trihydrate”, Int. J. Pharm.; 1992, 86, 79-88.
N. Dixit, S. Maurya, et. al., “Sustained Release Drug Delivery System,” Indian Journal of Research in Pharmacy and Biotechnology; 2013, 1(3), 305-9.
H. Patel, V. Shah, et. al., “New pharmaceutical excipients in solid dosage forms – A review,” International Journal of Pharmacy and Life Sciences; 2011, 2(8), 1006-19.
B. Parashar, A. Chauhan, et. al.,“Formulation and evaluation aspects of tablets-an overview,”Asian Journal of Pharmaceutical Research; 2012, 2(1), 2249-3387.
Zeria Pharmaceutical Co.,“A slow releasing pharmaceutical oral formulation comprising a high viscosity water soluble polymer”, Japanese Patent No. 63-14715, 1998.
Maunkonda K, padmashree K, et. al., “Comparative study of hydrophilic polymers for sustained drug delivery of lamivudine”, International Journal of Pharmaceutical Archives; 2014, 3 (9), 510-517.
Nagiat TH, Babu RC, et. al., “Influence of sodium cmc and hpmc on the physical characteristics of ofloxacin floating matrix tablets”, British Journal of Pharmaceutical Research; 3(3): 508–522, 2013.
Samal HB, et. al., “Formulation, Characterization and In–vitro Evaluation of Floating Microspheres of Nateglinide”, International Journal of Pharma and Bio Sciences; 2011; 2(1): 20–11.
Sohn Y.T., Rhee, et. al., “Polymorphism of clarithromycin”, Arch. Pharm. Res.; 2000, 23: 381-384.
Nur, A. O., Zhang, et. al.,"Captopril floating and /or bioadhesive tablets: design and release kinetics" Drug Dev. Ind. Pharm; 2000, 26, 965-969.
Peppas, N. A., and Korsmeyer, R.W., “Dynamically swelling hydro-gels in controlled release applications”, in: N.A. Peppas (Ed.), Hydrogels in Medicine and Pharmacy, CRC Press,Boca Raton; 1986, 3, 109–13
Dhawan S, Varma M, et. al., “High molecular weight poly (ethylene oxide) – based drug delivery systems Part I: Hydrogels and hydrophilic matrix systems”, Pharm Technol; 2005, 29:72-9
Li H, Hardy JH, et. al., “Effect of drug solubility on polymer hydration and drug dissolution from polyethylene (PEO) matrix tablets”, AAPS PharmSciTech; 2008, 9:437-43.
S.Niazi, “Hand book of pharmaceutical manufacturing formulation:Compressed solid products,”USA: Informa Health Care; 2009; 1(2), 62-80.
Montgomery, D. C., et. al., "Introduction to factorial deign" in: Design and Analysis of Experiments, 5th ed. Wiley India Pvt. Ltd., New Delhi; 2004, 170-217.
Ahlneck, C.Waltersson, et. al., “Factorial designs in pharmaceutical preformulation studies II. Studies on drug stability and compatibility in the solid state”, Acta Pharm. Suer.;1986, 23:139- 150.
J.Bhatia, R. Kaur, et. al., “Formulation and Optimization of Hydrochlorothiazide mouth dissolving tablets by using co-processed superdisintegrants,” International Journal of Pharmaceutical Sciences Review and Research; 2013, 21(2), 46-51.
Baumgartners S, Kristal J, et. al., “Optimization of floating matrix tablets and evaluation of their gastric residence time” Int.J.Pharm; 2000, 195(1–2): 125–135.
Schwartz BJ, Connor RE, et. al., “Optimization technique in Pharmaceutical Formulations and processing, Drugs and Pharmaceutical Sciences, In, Modern Pharmaceutics”, (Banker, J. S., Rhodes, T. C., Eds.) Marcel Dekker, Inc, New York; 1996, (72) 3: 727-754.
Donbrow M, Samuelov Y, et. al., “Zero order drug delivery from double–layered porous films: Release rate profiles from ethyl cellulose, hydroxypropylcellulose and polyethylene glycol mixtures”, J Pharm Pharmacol; 1980, 32: 463–70.
Peppas, N. A., et. al., “Analysis of Fickian and non-Fickian drug release from polymers”, Pharm. Acta. Helv.; 1985, 60,110– 111.
S. Dash, P. Murthy, et. al., “Kinetic modeling on drug release from controlled drug delivery systems,”Acta Poloniae Pharmaceutica Drug Research; 2010, 67(3), 217-23.
ICH Guideline Q1A (R2). Stability Testing of New Drug Substances and Products; (2003). http: //www. ich. org/LOB/media/MEDIA419.
M. Kaur, G. Kaur, et. al., “Overview on stability studies,”International Journal of Pharmaceutical, Chemical and Biological Sciences; 2013, 3(4), 1231-41.